A Study of CCCTC-binding Factor (CTCF) in Infantile Hemangiomas

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2009 by Yale University.
Recruitment status was  Recruiting
Information provided by:
Yale University
ClinicalTrials.gov Identifier:
First received: September 9, 2009
Last updated: NA
Last verified: September 2009
History: No changes posted

The purpose of this study is to evaluate the genotype of CTCF, a proven transcription factor, in patients with infantile hemangiomas and to monitor tumor growth. The investigators aim to determine whether or not the CTCF genotype might serve as an early and reliable predictor of tumor growth.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Infantile Hemangioma Tumor Size and C/T Polymorphism Within CTCF Binding Site Six

Resource links provided by NLM:

Further study details as provided by Yale University:

Biospecimen Retention:   Samples With DNA

Over the course of the study, one blood draw will be performed on each patient. This blood will be used for genetic analysis.

Estimated Enrollment: 100
Study Start Date: September 2009
Estimated Study Completion Date: May 2011
Patients with Infantile Hemangiomas

Detailed Description:

This study seeks to examine a potential relationship between CTCF genotype and hemangioma size and growth rate. In addition to the initial visit, patients will return to our clinic for evaluation at two weeks, one month, two months, six months, and one year. At each visit, patients' hemangiomas will be measured and photographed. At one point over the course of evaluation, a blood sample will be taken from each patient for evaluation of C/T polymorphism at CTCF binding site six.


Ages Eligible for Study:   up to 1 Year
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Patients to be recruited will include infants with hemangiomas on any part of their body.


Inclusion Criteria:

  • Hemangioma must appear within one month prior to enrollment

Exclusion Criteria:

  • Hemangioma appeared before one month prior to enrollment
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00974129

Contact: Alexandra C Sowa, BA, MA 443-386-3808 Alexandra.Sowa@yale.edu

United States, Connecticut
Yale Dermatology Associates Recruiting
New HAven, Connecticut, United States, 06519
Contact: Alexandra Sowa, BA, MA    443-386-3808    Alexandra.Sowa@yale.edu   
Principal Investigator: Richard Antaya, MD         
Sponsors and Collaborators
Yale University
Principal Investigator: Deepak Narayan, MD Yale University
  More Information

No publications provided

Responsible Party: Dr. Deepak Narayan, Yale University
ClinicalTrials.gov Identifier: NCT00974129     History of Changes
Other Study ID Numbers: 0507000430, Yale-0430
Study First Received: September 9, 2009
Last Updated: September 9, 2009
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Hemangioma, Capillary
Neoplasms, Vascular Tissue
Neoplasms by Histologic Type

ClinicalTrials.gov processed this record on April 17, 2014